Compare GT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GT | ORIC |
|---|---|---|
| Founded | 1898 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2005 | 2020 |
| Metric | GT | ORIC |
|---|---|---|
| Price | $4.17 | $9.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | $6.00 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 8.6M | 2.0M |
| Earning Date | 11-04-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,280,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.09 | $7.23 |
| 52 Week High | $10.62 | $14.68 |
| Indicator | GT | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 39.31 |
| Support Level | $4.09 | $7.62 |
| Resistance Level | $6.33 | $11.51 |
| Average True Range (ATR) | 0.21 | 1.01 |
| MACD | 0.04 | -0.15 |
| Stochastic Oscillator | 7.00 | 17.12 |
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific. The majority of its revenue is generated from the Americas business, which develops, manufactures, distributes, and sells tires and related products and services in North, Central, and South America, along with selling tires to various export markets, mainly through intersegment sales.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.